SALT LAKE CITY -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, today announced the access details for CEO Dwight Egan's presentation on the Company's significant growth, profitability, and future objectives at H.C. Wainwright's 22nd Annual Global Investment Conference on Monday, September 14th at 10:00 ET.


Viewers can register to access the live presentation at the following link, where it will also be archived for 90 days: 

More information about the conference may be found here.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.